Mizuho Securities Sticks to Its Buy Rating for Syneos Health (SYNH)

In a report released yesterday, Ann Hynes from Mizuho Securities reiterated a Buy rating on Syneos Health (SYNHResearch Report), with a price target of $94.00. The company’s shares closed last Friday at $70.91, close to its 52-week low of $66.73.

According to, Hynes is a 5-star analyst with an average return of 8.4% and a 56.3% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Quest Diagnostics, and Molina Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Syneos Health with a $92.86 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $104.18 and a one-year low of $66.73. Currently, Syneos Health has an average volume of 779.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded on August 13, 2010 and is headquartered in Morrisville, NC.

Read More on SYNH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More